Creatine transporter deficiency (CTD) is a rare X-linked disorder of creatine transport caused by pathogenic variants in SLC6A8 (Xq28). CTD features include developmental delay, seizures, and autism spectrum disorder. This study was designed to investigate CTD cardiac phenotype and sudden death risk.
We performed a cross-sectional analysis of CTD males between 2017 and 2020. Subjects underwent evaluation with electrocardiogram (ECG), echocardiography, and ambulatory ECG with comparable analysis in creatine transporter deficient mice (Slc6a8−/y) using ECG, echocardiography, exercise testing, and indirect calorimetry.
Eighteen subjects with CTD (18 males, age 7.4 [3.8] years) were evaluated: seven subjects (39%) had QTc ≥ 470 milliseconds: 510.3 ± 29.0 vs. 448.3 ± 15.9, P < 0.0001. The QTc ≥ 470 milliseconds cohort had increased left ventricular internal dimension (diastole) ([LVIDd] Z-score: 0.22 ± 0.74, n = 7 vs. −0.93 ± 1.0, n = 11, P = 0.0059), and diminished left ventricular posterior wall dimension (diastole) ([LVPWDd, in mm]: 5.0 ± 0.6, n = 7 vs. 5.7 ± 0.8, n = 11, P = 0.0183), when compared to subjects with normal or borderline QTc prolongation. Similar ECG and echocardiographic abnormalities were seen in Slc6a8−/y mice. Additionally, Slc6a8−/y mice had diminished survival (65%).
Prolonged QTc and abnormal echocardiographic parameters consistent with developing cardiomyopathy are seen in some male subjects with CTD. Slc6a8−/y mice recapitulated these cardiac abnormalities. Male CTD subjects may be at increased risk for cardiac dysfunction and sudden death.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data will be made available upon request to first, corresponding, or senior authors. Genomic data will be made available provided related NIH and NICHD privacy guidelines can be fully met. De-identified genomic data will be provided upon request.
Rosenberg, E. H. et al. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. Hum. Mutat. 28, 890–896 (2007).
Mercimek-Mahmutoglu, S. & Salomons, G. S. in GeneReviews (eds Adam, M. P. et al.) Creatine deficiency syndromes (University of Washington, Seattle, 1993).
Rosenberg, E. H. et al. High prevalence of SLC6A8 deficiency in x-linked mental retardation. Am. J. Hum. Genet. 75, 97–105 (2004).
Newmeyer, A., Cecil, K. M., Schapiro, M., Clark, J. F. & Degrauw, T. J. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. J. Dev. Behav. Pediatr. 26, 276–282 (2005).
Stromberger, C., Bodamer, O. A. & Stöckler-Ipsiroglu, S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J. Inherit. Metab. Dis. 26, 299–308 (2003).
Neubauer, S. et al. Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation. 100, 1847–1850 (1999).
Guimbal, C. & Kilimann, M. W. A Na+-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J. Biol. Chem. 268, 8418–8421 (1993).
Salomons, G. S. et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am. J. Hum. Genet. 68, 1497–1500 (2001).
van de Kamp, J. M. et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J. Med. Genet. 50, 463 (2013).
Anselm, I. A., Coulter, D. L. & Darras, B. T. Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8. Neurology. 70, 1642–1644 (2008).
Nozaki, F., Kumada, T., Shibata, M., Fujii, T., Wada, T. & Osaka, H. A family with creatine transporter deficiency diagnosed with urinary creatine/creatinine ratio and the family history: the third Japanese familial case. Hattatsu Brain Dev. 47, 49–52 (2015).
Priori, S. G. et al. Risk stratification in the long-QT syndrome. N. Engl. J. Med. 348, 1866–1874 (2003).
Baroncelli, L. et al. A novel mouse model of creatine transporter deficiency. F1000research. 3, 228 (2014).
Baroncelli, L. et al. A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. Hum. Mol. Genet. 25, 4186–4200 (2017).
McKeon, A., Vaughan, C. & Delanty, N. Seizure versus syncope. Lancet Neurol. 5, 171–180 (2006).
Medford, B. A., Bos, J. M. & Ackerman, M. J. Epilepsy misdiagnosed as long QT syndrome: it can go both ways. Congenit. Heart Dis. 9, E135–E139 (2014).
Taggart, N. W., Haglund, M. C., Tester, D. J. & Ackerman, M. J. Diagnostic miscues in congenital long-QT syndrome. Circulation. 115, 2613–2620 (2007).
Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiog. 28, 1–39.e14 (2015).
Levin, M. D. et al. Melanocyte-like cells in the heart and pulmonary veins contribute to atrial arrhythmia triggers. J. Clin. Invest. 119, 3420–3436 (2009).
Yang, Z. H. et al. Dietary palmitoleic acid attenuates atherosclerosis progression and hyperlipidemia in low‐density lipoprotein receptor‐deficient mice. Mol. Nutr. Food Res. 63, 1900120 (2019).
Kleiber, M. The Fire of Life: An Introduction to Animal Energetics. (Wiley, New York, 1961).
Meister, J. et al. Metabolic effects of skeletal muscle-specific deletion of beta-arrestin-1 and -2 in mice. PLoS Genet. 15, 1–17 (2019).
Team RCR: A language and environment for statistical computing. (2018). https://cran.microsoft.com/snapshot/2014-09-08/web/packages/dplR/vignettes/xdate-dplR.pdf.
Wickham H. Ggplot2, elegant graphics for data analysis. (2009). https://link.springer.com/book/10.1007%2F978-3-319-24277-4#about.
Crilley, J. G. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41, 1776 (2003).
Ormerod, J. O. M., Frenneaux, M. P. & Sherrid, M. V. Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat. Rev. Cardiol. 13, 677–687 (2016).
Maron, B. J., Gottdiener, J. S., Bonow, R. O. & Epstein, S. E. Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by m-mode echocardiography. Identification by wide-angle two-dimensional echocardiography. Circulation. 63, 409–418 (1981).
Cutler, M. J., Jeyaraj, D. & Rosenbaum, D. S. Cardiac electrical remodeling in health and disease. Trends Pharmacol. Sci. 32, 174–180 (2011).
Hill, J. A. Electrical remodeling in cardiac hypertrophy. Trends Cardiovas. Med. 13, 316–322 (2003).
Hill, J. A. Hypertrophic reprogramming of the left ventricle: translation to the ECG. J. Electrocardiol. 45, 624–629 (2012).
Wang, Y. & Hill, J. A. Electrophysiological remodeling in heart failure. J. Mol. Cell. Cardiol. 48, 619–632 (2010).
Heinrich, T. & Ingwall, J. S. Creatine—a dispensable metabolite? Circ. Res. 112, 878–880 (2013).
Schneider, J. E. et al. Cardiac structure and function during ageing in energetically compromised guanidinoacetate n-methyltransferase (GAMT)-knockout mice—a one year longitudinal mri study. J. Cardiovasc. Magn. Reson. 10, 9 (2008).
Schneider, J. E. et al. In vivo cardiac 1h-mrs in the mouse. Magn. Reson. Med. 52, 1029–1035 (2004).
Hove, M. T. et al. Creatine uptake in mouse hearts with genetically altered creatine levels. J. Mol. Cell. Cardiol. 45, 453–459 (2008).
Dzeja, P. P. et al. Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency. J. Physiol. 589, 5193–5211 (2011).
Craig, L. et al. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ. Res. 112, 945–955 (2013).
Hove, M. T. et al. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-n-methyltransferase–knockout mice. Circulation. 111, 2477–2485 (2005).
Faller, K. M. E. et al. Impaired cardiac contractile function in arginine: glycine amidinotransferase knockout mice devoid of creatine is rescued by homoarginine but not creatine. Cardiovasc. Res. 114, 417–430 (2018).
Tian, R. & Ingwall, J. S. Energetic basis for reduced contractile reserve in isolated rat hearts. Am. J. Physiol. 270, H1207–H1216 (1996).
The National Center for Advancing Translational Sciences (NCATS), NICHD, National Institute of Mental Health (NIMH), and National Heart, Lung, and Blood Institute (NHLBI) intramural programs funded this work. We express our sincere gratitude to the subjects and their families for supporting this work. We also thank the Association for Creatine Deficiencies. The Slc6a8−/y mice were provided by Laura Baroncelli (Italian National Research Council). We acknowledge support by Lumos Pharmaceuticals and Ultragenyx. We also acknowledge the NHLBI pathology and mouse phenotyping cores for their assistance in data collection and data analysis. Each author has reviewed the manuscript and has agreed to its submission.
Study approval was obtained from the IRB at the National Institute of Child Health and Human Development (NICHD), NIH. All guidelines for good clinical practice were followed. Guardians provided written consent. Assent was obtained when possible. Animal studies: All studied experiments performed had prior approval from NICHD animal studies committee and were carried out in strict compliance with all NIH guidelines and ethical regulations.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Levin, M.D., Bianconi, S., Smith, A. et al. X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model. Genet Med (2021). https://doi.org/10.1038/s41436-021-01224-8